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Abstract: Tetrodotoxin (TTX) is starting to appear in molluscs from the European waters and is
a hazard to seafood consumers. This toxin blocks sodium channels resulting in neuromuscular
paralysis and even death. As a part of the risk assessment process leading to a safe seafood level for
TTX, oral toxicity data are required. In this study, a 4-level Up and Down Procedure was designed
in order to determine for the first time the oral lethal dose 50 (LD50) and the No Observed Adverse
Effect Level (NOAEL) in mice by using an accurate well-characterized TTX standard.
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1. Introduction
Tetrodotoxin (TTX) and about 30 of its analogues are marine neurotoxins [1] first detected in
puffer fishes [2], but recently identified in crustacea, gastropods, and bivalves [3]. TTX production is
attributed to bacteria such as Pseudomonas and Vibrio spp. [4–7] that can reach animals through the
food chain [8]. Bacteria may be eliminated in shellfish during cooking, but TTX is heat stable and
cannot be destroyed in this process, and therefore is a risk to seafood consumers.
TTX has been responsible for human intoxications. It blocks sodium channels [9,10] and terminates
nerve conduction and muscle action potentials [11], leading to progressive paralysis and, in extreme
cases, to death from respiratory and heart failure [12,13].
Even though initially TTX distribution was limited to temperate climate zones, recent studies
have determined its presence in European bivalves [14,15]. The presence of this toxin in shellfish
creates a new problem due to the fact that there is no legal limit for TTX content in seafood within the
European Union (EU). According to the current EU legislative requirements (Regulation 853/2004/EC;
Regulation 854/2004/EC) only fishery products derived from poisonous fish of the family Tetraodontidae
must not be placed on the market. The detection of TTX in shellfish and expansion of its geographical
distribution require a risk assessment process leading to a safe seafood level for TTX as well as an
adaptation of the legislation to control the presence of TTX in seafood. As a part of this process,
information on the oral toxicological properties of TTX is needed.
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2. Results
In the Up and Down Procedure, all mice administrated with 1000 µg/kg BW TTX by oral gavage
died during the 2 h experiment. Therefore, 500 µg/kg BW was the dose for the second level, where
four of the five mice died. In the third level, four of the seven mice treated with 250 µg/kg BW died,
which lead to a reduction to 125 µg/kg BW for the fourth level, in which all of the mice survived
(Table 1).
Table 1. Mortality induced by gavage administration of tetrodotoxin (TTX) to mice and survival times
corresponding with each treatment.
Dose (µg/kg) Mortality Survival Times (min)
1000 3/3 7, 18, 37
500 4/5 58, 3, 2, 1




Apathy was a symptom quickly observed after the treatment with all doses. Piloerection, squint-eyes,
or circling appeared less frequently. Over time, paralysis of extremities became more visible and close
to death, some mice had seizures (Table 2). Mice treated with high doses died within minutes; they
had seizures soon after the toxin administration that could mask prior paralysis of the extremities.
Table 2. Symptoms registered after tetrodotoxin (TTX) administration. Ratio between mice with the
symptom versus the total mice treated.
Symptoms
TTX Dose (µg/kg)
1000 500 250 125 75 25
Apathy 3/3 5/5 7/7 9/9 0/9 0/9
Piloerection 0/3 0/5 1/7 2/9 0/9 0/9
Paralysis of
extremities 3/3 2/5 2/7 0/9 0/9 0/9
Seizures 3/3 2/5 2/7 0/9 0/9 0/9
Circling 0/3 2/5 1/7 0/9 0/9 0/9
Squint eyes 0/3 1/5 0/7 0/9 0/9 0/9
Death was usually by induced by cardiorespiratory failure. With the aim to determine the No
Observed Adverse Effect Level (NOAEL), 9 mice were also administrated 75 and 25 µg/kg BW TTX.
All those mice survived (Table 1) and showed no clinical signs of toxicity during the 2 h experiment.
The optimized 4-level Up and Down Procedure revealed a dose-dependent mortality induced
by TTX. In Figure 1, all the results are presented in a semi-logarithmic scale as the percentage of mice
mortality versus the administered toxin. Based on those data, the oral LD50 of TTX was estimated to
be 232 µg/kg BW and the oral LD100 to be 1000 µg/kg BW by a nonlinear regression fitting procedure
(GraphPad Prism 5., Version 5.01, ©1992-2007 GraphPad Software, Inc, La Jolla, CA, USA).























death within 7–8 h due  to respiratory  failure and cardiovascular collapse  [17]. Even  though most 
intoxicated people should fully recover usually within 24 h [13], it was also reported that death may 
occur in less than 30 min [18], indicating a rapid rate of absorption from the gastrointestinal tract. 
Although  hundreds  of  TTX  intoxication  cases  have  been  published  [19]  it  is  difficult  to  find  a 
correlation between toxin concentration and poisoning symptoms due to the scarce oral toxicity data. 
TTX is unequivocally toxic to mammals. In mice, the reported LD50 values were 2–10, 10–10.7, 12.5–













Figure 1. Dose response mortality curve of oral tetrodotoxin (TTX) in mice. Percentage lethality values
are plotted against concentration of the toxin. The LD50 value is indicated.
No macroscopic changes were observed in any organs of the mice treated with 25 µg/kg BW TTX,
and only one mouse exposed to 75 µg/kg BW TTX had the stomach moderately dilated. However,
all mice that received doses higher than 75 µg/kg BW had dilated stomachs with liquid and gas
accumulation, even though the small intestine showed similar aspects to the controls. Only some mice
administrated with 250 and 125 µg/kg BW TTX had duodenums that were moderately distended
with liquid content. All mice treated with 1000 µg/kg TTX had cardiac stiffness, hence no blood was
collected. TTX was successfully detected in blood samples from mice treated with 500 and 250 µg/kg
BW (Table 3).
Table 3. Tetrodotoxin (TTX) (ng/mL) quantified in blood samples by LC-MS/MS. Limit of detection
(LOD) and limit of quantification (LOQ) of the method were 0.5 ng/mL and 1 ng/mL, respectively.
Dose (µg/kg) TTX Level (ng/mL)
500 6.46 ± 1.91
250 1.29 ± 0.18
125 <LOQ
3. Discussion
TTX is a neurotoxin responsible for human poisoning due to the ingestion of food containing the
toxin [16]. In fatal cases, humans show neurological signs within 2–3 h after exposure followed by death
within 7–8 h due to respiratory failure and cardiovascular collapse [17]. Even though most intoxicated
people should fully recover usually within 24 h [13], it was also reported that death may occur in
less than 30 min [18], indicating a rapid rate of absorption from the gastrointestinal tract. Although
hundreds of TTX intoxication cases have been published [19] it is difficult to find a correlation between
toxin concentration and poisoning symptoms due to the scarce oral toxicity data. TTX is unequivocally
toxic to mammals. In mice, the reported LD50 values were 2–10, 10–10.7, 12.5–16 µg/kg BW for
intravenous, intraperitoneal i.p., and subcutaneous administration, respectively [13,14]. However,
at present there are no oral toxicity data of purified TTX.
In this context and taking into account duration, rapidity of onset, and the severity of sy ptoms,
the aim of the present study was to determine oral TTX toxicity in mice for 2 h by using a modified
4-level Up and Down Procedure. Our results indicated dose-dependent symptoms and mortality in
mice exposed to TTX by gavage. Animals died of cardiorespiratory failure sometimes after a period
of paralysis that supports the presence of biologically effective TTX concentrations in the blood [20].
In our study, the estimated oral LD50 = 232 µg/kg BW was 1.5–3 times lower than other values
previously published [16,18,21]. It is important to note that this is the first report of in vivo studies
using an accurate well-characterized TTX standard. This toxin at a dose of 75 and 25 µg/kg BW TTX
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did not cause any significant adverse effects, but higher doses induced at least clinical signs and
macroscopic alterations at the gastrointestinal level. Therefore, according to these results we define for
the first time the oral NOAEL of TTX for mice as 75 µg/kg BW.
4. Conclusions
TTX has now been identified in shellfish within the European waters [14,15], posing a problem to
the seafood industry and a serious hazard to consumers. This fact should alert health authorities to the
need for potential preventive measures. The oral LD50 (232 µg/kg BW) and NOAEL (75 µg/kg BW)
values determined in this study may be used as a starting point for further risk assessment processes
leading to a safe seafood level for TTX in the EU [22].
5. Materials and Methods
In vivo studies were performed with Swiss female mice weighing 18–21 g. All animal procedures
described in the manuscript were carried out in conformity to European legislation (EU directive
2010/63/EU) and Spanish legislation (Real decreto 53/2013, Decreto 296/2008) and to the principles
approved by the Institutional Animal Care Committee of the Universidad de Santiago de Compostela
Code: AE-LU-002/13/FUN 01/TOX05/CON.AMB.[08]/LMBL8.
TTX used for all the experiments was obtained from CIFGA (Lugo, Spain). The stock solution
was initially solved in aqueous [AcOH] = 1 × 10−3 M. Immediately before administration, TTX was
diluted in 0.9% saline solution to achieve each dose (toxin carrier concentration <2.5%).
For the experimental procedure, mice were fasted overnight (12 h) with 5% glucosated serum
ad libitum. The next morning they received a single oral dose of TTX by gavage (10 mL/kg) and
were placed individually in metabolic cages for the following 2 h with free access to chow and water.





      een identified in shellfish within the European waters [14,15], posing a problem 
o th  seafood industry and a serious hazard to consumers. This fact should aler  health authorities 
to the need for potential preventive measur s. The oral LD50 (232 μg/kg BW) and NOAEL (75 μg/kg 
BW) values det rmined  in  this study may be used as a  starting point  fo   further  risk assessment 
processes leading to a safe s af od level for TTX in the EU [22]. 
5.  aterials a   et s 
I   i o st ies  ere  erfor ed  it  S iss fe ale  ice  ei i  18–21  .  ll a i al  roce res 
escri e   i   t e  a scri t  ere carrie  o t  i  co for it   to  ro ea   le islatio   (   irecti e 
2010/63/EU) and Spanish legislation ( eal  ecreto 53/2013,  ecreto 296/2008) and to t e  ri ci les 
a r e    t e I stit ti al  i al  are  ittee  f t e  i ersi a   e Sa tia   e  stela 
e:  ‐ ‐002/13/FUN 01/TOX05/CON.AMB.[08]/LMBL8. 
  se  f r all t e ex eri e ts  as  tai e  fr   I  ( ,  ai ).  e st c  s l ti  
as i itiall  s l e  in aqueous [AcOH] = 1 × 10−3  . I e iately  ef re a i istrati ,    as 
il te  i  0.9  sali e s l ti  t  ac ie e eac   se (t xi  carrier c ce trati  <2.5 ). 
r t e e eri e tal  r ce re,  ice  ere faste   er i t (12  )  it  5   l c sate  ser  
a  li it .  e  ext morning they received a single oral dose of TTX by gavage (10 mL/kg) and were 
placed individually in metabolic cages for the following 2 h with free access to chow and water. A 
modified 4‐level Up and Down Procedure  [23] was  set up  to  eter ine  t e  let l  se    ( 5 ) 
( i re  ). 
 
Figure 2. The 4‐level Up and Down Procedure designed for the in vivo TTX study. 




Symptoms  were  observed  continuously  during  the  whole  experiment  (2  h  after  toxin 
administration). Animals  that  survived were euthanized by CO2  inhalation. Macroscopic analysis 







mL/min, and  the  injection volume was 5 μL. The  chromatographic  conditions  consisted of  initial 
Figure 2. The 4-level Up and Down Procedure designed for the in vivo tetrodotoxin (TTX) study.
e ber of mice was increased at each design level: 3 animals on the first level, 5 on the second,
7 on the third, and 9 on the fourth. The starting dose was 1000 µg/kg BW, and the dose for the next
level was decreased if more than 50% of the mice died or increased if less than 50% of the mice died.
Symptoms were observed continuously during the whole experiment (2 h after toxin administration).
Animals that survived were euthanized by CO2 inhalation. Macroscopic analysis was performed in all
mice immediately after death. Time of death was indicate by last gasping breath. Blood was collected
by cardiac puncture and stored at −80 ◦C until the time of analysis. Then, the extraction procedure
was performed according to Tsujimura et al. 2015 [24].
Toxins 2017, 9, 75 5 of 6
The analysis of TTX was carried out using an Acquity UPLC BEH Amide 100 mm × 2.1 mm × 1.7 µm
column (Waters, Milford, CT, USA), equipped with a 0.2 µm Acquity UPLC in-line filter. Mobile phases
were as follows; A: water and B: acetonitrile (95% v/v) both containing 2 mM of ammonium formate
and 3.6 mM of formic acid. The column temperature was set at 30 ◦C, flow was settled at 0.4 mL/min,
and the injection volume was 5 µL. The chromatographic conditions consisted of initial conditions of
10%:90%, held for 1 min, then a linear gradient to 50%:50% over 3 min, held for 1 min. The column
was then re-equilibrated using a linear gradient to 10%:90% over 0.1 min and then held for 1.5 min.
Mass analysis was performed using a Xevo TQ MS mass spectrometer from Waters. (Manchester, UK)
operated with the following parameters (ESI source): capillary potential 2.7 kV, cone voltage 39 V,
desolvation temperature 350 ◦C, desolvation gas flow 850 L/h N2, cone gas flow 50 L/h N2, source
temperature 150 ◦C, collision energy 40 V. Argon was used as the collision gas at 4.5 × 10−3 mbar. TTX
was quantified against the certified reference standard CRM-03-TTXs sourced from Laboratorio CIFGA
S.A. (Lugo, Spain. 81.2 ± 4.0 µmol TTXs/kg and 9.92 ± 0.70 µmol 4,9-anhTTX/kg, purity >96%) by
using the following transitions: TTX and 4-epiTTX (m/z 320.2 > 178.1/162.0) and 4,9-anhydro TTX
(302.1>162.0/150.0). Calibration standards were prepared from standard solution by dilution into
acetonitrile/[AcOH] = 0.03 M (70:30 v/v) (standard dilution solvent) in polypropylene vials. A six
point calibration was generated with variable concentrations ranging from 1 to 20 ng/mL.
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